Researchers at Mount Sinai’s Icon School of Medicine have found that pre -birth exhibitions for Estaminophen may increase the risk of neurode -controversial disorders, including autism spectrum disorder and attention deficit/hyperactivity disorder (ADHD). This study appeared on August 14 BMC Environmental HealthIs the first person to apply hard navigation guide procedures to regularly review the hardness and quality of scientific literature.
Acetaminophen (often sold under the brand name Telonol®, and is known as paracetamol outside the United States and Canada) is the most commonly used drug and fever medicine during pregnancy and is used by more than half of pregnant women worldwide. So far, acetaminophen is considered the safest option for headaches, fever and other pain management. The analysis of the Mount Sena -led team of 46 studies, which includes more than 100,000 participants’ data in several countries, challenges the idea and indicates the need for both caution and further study.
The Navigation Guide Systemic Review Procedure is a framework of gold quality for environmental health data synthesis and diagnosis. This approach allows researchers to evaluate and classify the risk of prejudice for each study, such as selective reporting of results or incomplete data, as well as the strength of the evidence and the quality of the study individually and collectively.
“Our results show that high -quality studies are more likely to show a link between pre -birthdestive exposure and autism and the growing risks of ADHD,” said MD, PhD, Assistant Professor of Population Health Science and Policy, and Environmental Medicine and Climate Science. “In view of the widespread use of this drug, a slight increase in risk can also lead to major health implications.”
This article also detects biological mechanisms that can explain the association between the use of acetaminophen and the disorders. Acetaminophine is known to cross the plastic obstruction and can trigger oxidative stress, affect hormones, and can cause episode genetic changes that fetus interferes with brain growth.
Although this study does not indicate that acetaminophine directly causes neurodepareous disorders, the results of the research team reinforce evidence of the relationship and raise concerns about current clinical methods.
Researchers demand cautious, timely use of estaminophine during pregnancy under medical supervision. Clinical guidelines were updated to better balance the benefits and risks. And further research to confirm these results and to identify safe alternatives to pain and fever management in expected mothers.
Dr. Prada stressed, “Pregnant women should not quit taking medicine without consulting their doctors.” “Non -treatment pain or fever can also harm the baby. Our study highlights the importance of discussing the safest approach to health care providers and considering non -drug powers whenever possible.”
With the diagnosis of autism and ADHD worldwide, these results have important implications for public health policy, medical guidelines and patients’ education. The study also highlights the urgent need for pharmaceutical innovation to provide safe alternatives for pregnant women.
The study was done in collaboration with the University of California, Los Angeles. University of Massachusetts Lovil; And Harvard Chen School of Public Health.
Financial support for this study was provided by the National Cancer Institute (U54CA267776), the National Institute of Environmental Health Science (R35ES031688), and the National Institute on Aging (U01ag088684).
